EA-2353

EA-2353 · Endogena Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for EA-2353, covering 2024-10-15 to 2024-10-15. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa [Phase 1, Phase 2]

See pricing